579 related articles for article (PubMed ID: 34537184)
1. Left atrial appendage occlusion vs novel oral anticoagulation for stroke prevention in atrial fibrillation: rationale and design of the multicenter randomized occlusion-AF trial.
Korsholm K; Damgaard D; Valentin JB; Packer EJS; Odenstedt J; Sinisalo J; Putaala J; Næss H; Al-Jazi MA; Karlsson JE; Pontoppidan J; Modrau B; Hjort J; Matzen KL; Johnsen SP; Nielsen-Kudsk JE
Am Heart J; 2022 Jan; 243():28-38. PubMed ID: 34537184
[TBL] [Abstract][Full Text] [Related]
2. COMPARE LAAO: Rationale and design of the randomized controlled trial "COMPARing Effectiveness and safety of Left Atrial Appendage Occlusion to standard of care for atrial fibrillation patients at high stroke risk and ineligible to use oral anticoagulation therapy".
Huijboom M; Maarse M; Aarnink E; van Dijk V; Swaans M; van der Heijden J; IJsselmuiden S; Folkeringa R; Blaauw Y; Elvan A; Stevenhagen J; Vlachojannis G; van der Voort P; Westra S; Chaldoupi M; Khan M; de Groot J; van der Kley F; van Mieghem N; van Dijk E; Dijkgraaf M; Tijssen J; Boersma L
Am Heart J; 2022 Aug; 250():45-56. PubMed ID: 35537503
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of left atrial appendage occlusion versus direct oral anticoagulation in patients with atrial fibrillation and prior ischemic stroke: A propensity-score matched study.
Korsholm K; Valentin JB; Damgaard D; Diener HC; Camm AJ; Landmesser U; Hildick-Smith D; Johnsen SP; Nielsen-Kudsk JE
Int J Cardiol; 2022 Sep; 363():56-63. PubMed ID: 35780932
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes Associated With Left Atrial Appendage Occlusion Versus Direct Oral Anticoagulation in Atrial Fibrillation.
Nielsen-Kudsk JE; Korsholm K; Damgaard D; Valentin JB; Diener HC; Camm AJ; Johnsen SP
JACC Cardiovasc Interv; 2021 Jan; 14(1):69-78. PubMed ID: 33413867
[TBL] [Abstract][Full Text] [Related]
5. Non-vitamin K antagonist oral anticoagulation versus left atrial appendage occlusion for primary and secondary stroke prevention after cardioembolic stroke.
Paiva L; Coelho J; Barra S; Costa M; Sargento-Freitas J; Cunha L; Gonçalves L
Rev Port Cardiol (Engl Ed); 2021 May; 40(5):357-365. PubMed ID: 34187638
[TBL] [Abstract][Full Text] [Related]
6. Comparison of anticoagulation with left atrial appendage closure after atrial fibrillation ablation: Rationale and design of the OPTION randomized trial.
Wazni OM; Boersma L; Healey JS; Mansour M; Tondo C; Phillips K; Doshi R; Jaber W; Hynes E; Allocco DJ; Reddy VY
Am Heart J; 2022 Sep; 251():35-42. PubMed ID: 35526570
[TBL] [Abstract][Full Text] [Related]
7. Left atrial appendage occlusion in recurrent ischaemic stroke, a multicentre experience.
Galloo X; Carmeliet T; Prihadi EA; Lochy S; Scott B; Verheye S; Schoors D; Vermeersch P
Acta Clin Belg; 2022 Apr; 77(2):255-260. PubMed ID: 32951514
[TBL] [Abstract][Full Text] [Related]
8. Over 1-year efficacy and safety of left atrial appendage occlusion versus novel oral anticoagulants for stroke prevention in atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials and observational studies.
Li X; Wen SN; Li SN; Bai R; Liu N; Feng L; Ruan YF; Du X; Dong JZ; Ma CS
Heart Rhythm; 2016 Jun; 13(6):1203-14. PubMed ID: 26724488
[TBL] [Abstract][Full Text] [Related]
9. Left Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation : A Decision Analysis.
Chew DS; Zhou K; Pokorney SD; Matchar DB; Vemulapalli S; Allen LA; Jackson KP; Samad Z; Patel MR; Freeman JV; Piccini JP
Ann Intern Med; 2022 Sep; 175(9):1230-1239. PubMed ID: 35969865
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of a randomized clinical trial to compare two antithrombotic strategies after left atrial appendage occlusion: double antiplatelet therapy vs. apixaban (ADALA study).
Flores-Umanzor EJ; Cepas-Guillen PL; Arzamendi D; Cruz-González I; Regueiro A; Freixa X
J Interv Card Electrophysiol; 2020 Nov; 59(2):471-477. PubMed ID: 32986176
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of a randomized study comparing the Watchman FLX device to DOACs in patients with atrial fibrillation.
Kar S; Doshi SK; Alkhouli M; Camm AJ; Coylewright M; Gibson MC; Granger CB; Gurol ME; Huber K; Mansour M; Nair DG; Natale A; Pocock SJ; Reddy VR; Saliba W; Christen T; Allocco DJ; Ellenbogen KA; Leon MB
Am Heart J; 2023 Oct; 264():123-132. PubMed ID: 37279840
[TBL] [Abstract][Full Text] [Related]
12. Left atrial appendage closure for stroke prevention in nonvalvular atrial fibrillation: A current overview.
Ueno H; Imamura T; Tanaka S; Fukuda N; Kinugawa K
J Cardiol; 2023 May; 81(5):420-428. PubMed ID: 36400415
[TBL] [Abstract][Full Text] [Related]
13. Percutaneous Left Atrial Appendage Occlusion: An Emerging Option in Patients with Atrial Fibrillation at High Risk of Bleeding.
Cimmino G; Loffredo FS; Gallinoro E; Prozzo D; Fabiani D; Cante L; Salerno G; Cappelli Bigazzi M; Golino P
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34063719
[TBL] [Abstract][Full Text] [Related]
14. Double-blind, placebo-controlled randomised clinical trial to evaluate the effect of ASPIRIN discontinuation after left atrial appendage occlusion in atrial fibrillation: protocol of the ASPIRIN LAAO trial.
Chen M; Wang Q; Sun J; Zhang PP; Li W; Mo BF; Chen TZ; Tang X; Li YG;
BMJ Open; 2021 Mar; 11(3):e044695. PubMed ID: 33722871
[TBL] [Abstract][Full Text] [Related]
15. Clinical follow-up of left atrial appendage occlusion in patients with atrial fibrillation ineligible of oral anticoagulation treatment-a systematic review and meta-analysis.
Labori F; Bonander C; Persson J; Svensson M
J Interv Card Electrophysiol; 2021 Aug; 61(2):215-225. PubMed ID: 33580847
[TBL] [Abstract][Full Text] [Related]
16. Patient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials.
Friedman DJ; Du C; Wang Y; Agarwal V; Varosy PD; Masoudi FA; Holmes DR; Reddy VY; Price MJ; Curtis JP; Freeman JV
JACC Cardiovasc Interv; 2022 May; 15(9):950-961. PubMed ID: 35512918
[TBL] [Abstract][Full Text] [Related]
17. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.
Reddy VY; Doshi SK; Kar S; Gibson DN; Price MJ; Huber K; Horton RP; Buchbinder M; Neuzil P; Gordon NT; Holmes DR;
J Am Coll Cardiol; 2017 Dec; 70(24):2964-2975. PubMed ID: 29103847
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of left atrial appendage occlusion with multiple devices.
Radinovic A; Falasconi G; Marzi A; D'Angelo G; Limite L; Paglino G; Peretto G; Frontera A; Fierro N; Sala S; Della Bella P; Mazzone P
Int J Cardiol; 2021 Dec; 344():66-72. PubMed ID: 34599944
[TBL] [Abstract][Full Text] [Related]
19. Percutaneous Left Atrial Appendage Occlusion in Comparison to Non-Vitamin K Antagonist Oral Anticoagulant Among Patients With Atrial Fibrillation.
Noseworthy PA; Van Houten HK; Krumholz HM; Kent DM; Abraham NS; Graff-Radford J; Alkhouli M; Henk HJ; Shah ND; Gersh BJ; Friedman PA; Holmes DR; Yao X
J Am Heart Assoc; 2022 Oct; 11(19):e027001. PubMed ID: 36172961
[TBL] [Abstract][Full Text] [Related]
20. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation.
Osmancik P; Herman D; Neuzil P; Hala P; Taborsky M; Kala P; Poloczek M; Stasek J; Haman L; Branny M; Chovancik J; Cervinka P; Holy J; Kovarnik T; Zemanek D; Havranek S; Vancura V; Opatrny J; Peichl P; Tousek P; Lekesova V; Jarkovsky J; Novackova M; Benesova K; Widimsky P; Reddy VY;
J Am Coll Cardiol; 2020 Jun; 75(25):3122-3135. PubMed ID: 32586585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
